UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 18, 2022
(Exact Name of Registrant as Specified in Its Charter)
(Commission File Number)
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices, including zip code)
(215 ) 619-3200
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On January 18, 2022 STRATA Skin Sciences, Inc. (“STRATA”), a medical
technology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the
signing of a distribution agreement with JuveniL, the dermatology and aesthetics portion of Trimarco, Ltd., a leading distributor in Israel for
medical devices, to distribute STRATA’s XTRAC® excimer lasers in Israel.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation
S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation
language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
This report includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but
are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to generate the
growth in its core business, develop and grow an international recurring business model, the Company’s ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business,
competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona virus and political factors or conditions affecting the Company and the medical device industry in general, as well as more
specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this report are
made as of the date of the report, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring
after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Strata Skin Sciences Press Release Dated January 18, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
|
|
Date: January 18, 2022
|
By:
|
/s/ Christopher Lesovitz
|
|
|
|
|
Christopher Lesovitz
|
|
|
|
|
Chief Financial Officer
|
|
2
EXHIBIT 99.1
STRATA Skin Sciences Expands into Israel with Leading Medical Device Distributor
Enables STRATA to Commercialize and Market its XTRAC Excimer Lasers to an Estimated 300,000 Psoriasis and 160,000 Vitiligo Patients in
Israel
Horsham, Pa, January 18, 2022 —STRATA Skin Sciences,
Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that it has entered into an agreement with JuvenIL, the dermatology and
aesthetics portion of Trimaco, a leading distributor in Israel for medical devices and innovation, to supply STRATA’s XTRAC® excimer lasers in Israel.
“We believe that entering into the Israeli market presents a good opportunity for STRATA,” said Robert Moccia, President & CEO of STRATA Skin Sciences.
“Following approval to market our products in Israel, we identified JuvenIL as the ideal partner in the region. Through JuvenIL, we can now market our products to the entire Israeli population, of which there are an estimated 300,000 psoriasis and
160,000 vitiligo patients that can benefit from our laser treatment. We are confident that JuvenIL’s experienced team will be invaluable as they work with the more than forty major hospitals and four major Health Maintenance Organizations in Israel
to commercialize STRATA’s XTRAC excimer lasers.”
JuvenIL, based in Rehovot Israel, is the dermatology and aesthetics portion of Trimaco, a company that sells cutting-edge technologies to medical centers
across Israel.
“We are very excited to partner with STRATA Skin Sciences,” said Liraz Shlomoff, owner and founder of Trimaco. “Their state-of-the-art excimer lasers
utilized in the treatment of psoriasis, vitiligo and various other skin conditions fits well into our distribution network. We look forward to working with STRATA as they continue to expand into Israel.”
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the
treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis,
vitiligo, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.
STRATA’s unique US business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and
insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but
are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to generate the
growth in its core business, develop and grow an international recurring business model, the Company’s ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are
based on the Company’s current expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business,
competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona virus and political factors or conditions affecting the Company and the medical device industry in general, as well as more
specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release
are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances
occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact
|
Jack Droogan
|
|
|
|
(203) 585-4140
|
|
|
|
ir@strataskin.com
|
2